Discuss This Drug

axitinib

CHEBI:CHEBI_66910

Definition

An indazole substituted at position 3 by a 2-(pyridin-2-yl)vinyl group and at position 6 by a 2-(N-methylaminocarboxy)phenylsulfanyl group. Used for the treatment of advanced renal cell carcinoma after failure of a first line systemic treatment.

Chemical Information

Molecular Formula
C22H18N4OS
Molecular Mass
386.47000
Charge
0
SMILES
CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1
InChI
InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
InChIKey
RITAVMQDGBJQJZ-FMIVXFBMSA-N

Alternative Names

  • AG-013736
  • axitinib
  • axitinibum
  • Inlyta
  • N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide
  • N-methyl-2-({3-[(E)-2-(pyridin-2-yl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide

Treatment Applications

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

core#notation
CHEBI:66910
DRON_00010000
1242999
oboInOwl#hasDbXref
Wikipedia:Axitinib

Additional References

Wikipedia:Axitinib

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

core#notation
CHEBI:66910
rxcui
1243014
active_ingredient_strength
1 kg/kg
nui
N0000020000
pharm_class_epc
Kinase Inhibitor [EPC]
pharm_class
Receptor Tyrosine Kinase Inhibitors [MoA]
manufacturer_name
U.S. Pharmaceuticals
package_marketing_start_date
23-DEC-14
active_ingredient_name
AXITINIB
pharm_class_moa
Receptor Tyrosine Kinase Inhibitors [MoA]
unii
C9LVQ0YUXG
spl_set_id
8a903e31-936e-4ed7-8a59-59f32374f338
upc
0300690151113
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
oboInOwl#hasOBONamespace
chebi_ontology
DRON_00010000
1242999
generic_name
AXITINIB
oboInOwl#hasDbXref
Wikipedia:Axitinib
oboInOwl#id
CHEBI:66910
product_type
BULK INGREDIENT
marketing_category
BULK INGREDIENT
listing_expiration_date
20241231
route
ORAL
dosage_form
POWDER
marketing_start_date
20120127
labeler_name
U.S. Pharmaceuticals
product_ndc
54893-0043
spl_id
0cc327a8-40b2-4411-e063-6294a90a214f
package_ndc
54893-0043-5
package_description
15 kg in 1 DRUM (54893-0043-5)
brand_name
INLYTA
brand_name_base
INLYTA
application_number
NDA202324
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_65207
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
has_treatment
http://purl.obolibrary.org/obo/DOID_0081416
owl#annotatedSource
t268884
owl#someValuesFrom
t1101906
rdf-schema#range
https://w3id.org/def/predibionto#has_drug_113178
rdf-schema#domain
https://w3id.org/def/predibionto#has_side_effect31550